The FDA has granted orphan drug designation to ZEN-3694, a first-in-class BET bromodomain inhibitor being developed for NUT carcinoma—a rare, aggressive cancer driven by NUTM1 gene fusions and lacking any approved targeted…
The FDA has granted orphan drug designation to ZEN-3694, a first-in-class BET bromodomain inhibitor being developed for NUT carcinoma—a rare, aggressive cancer driven by NUTM1 gene fusions and lacking any approved targeted…